Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Inventory

Cash effect of the change in inventory; building inventory consumes cash.

SanofiNASDAQ: SNY

Inventory · Q2 FY2026 · quarter ended Jun 2026

Inventory turns negative

Q2 FY2026 inventory was -€1.12B, compared with €0 a year earlier. Trailing-twelve-month inventory was -€482.5M. Over 3 fiscal years it compounded at -63.7% a year.

Context

  • Inventory amounted to 0.1% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Inventory grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly inventory holds near -€1.12B or moves back toward the trailing-twelve-month quarterly average of -€120.63M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€1.12B— QoQ
Last fiscal yearDec 2025
-€44.02M-90.8% YoY
LTMJun 2026
-€482.5M— YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-90.8%——
3-year CAGR-63.7%——
5-year CAGR——
10-year CAGR——

Inventory history

EUR · from the cash flow

Latest · FY2025
(44.02M) EUR
Year-over-year change
+90.8%

Inventory vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
  • Inventory amounts to 1.0% of revenue for SNY, versus a peer median of 0.0%.
SNY Competitors
Inventory for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$1.18B USD—+94.2%1.8%
GILDGilead Sciences, Inc.LTM Jun 2026$638M USD-10.0%+49.5%2.1%
SNYSanofiLTM Jun 2026€482.5M EUR—-63.7%1.0%
AMGNAmgen Inc.LTM Jun 2026$346M USD-77.4%—0.9%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$41M USD-80.3%+38.7%0.1%
NVSNovartis AGLTM Jun 2026$40.84M USD-39.9%—0.1%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD—+98.2%0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD—-1.8%0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding SNY) —-58.7%+49.5%0.0%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.22B7.97B5.06B5.5B5.57B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
Deferred Income Tax(356M)(529M)(1.23B)(802M)(2.75B)
Stock-Based Compensation244M0000
Change in Working Capital1.41B(794M)413M(615M)2.03B
Accounts Receivables185M(500M)(472M)(28M)(1.36B)
Inventory(357M)(918M)(866M)(477M)(44.02M)
Accounts Payables451M340M258M789M449.17M
Other Working Capital1.13B284M1.49B(899M)2.98B
Other Non-Cash Items(349M)771M1.59B1.42B1.61B
Operating Cash Flow10.52B10.53B10.26B9.08B12.13B
Capital Expenditures(2.04B)(2.1B)(2.91B)(3.2B)(1.99B)
Acquisitions (Net)(5.59B)(1.34B)(2.63B)(2.52B)955.91M
Purchases of Investments(311M)(488M)(134M)0(11.37B)
Sales of Investments718M0000
Other Investing Activities(68M)1.86B(533M)1.35B11.74B
Investing Cash Flow(7.3B)(2.08B)(6.2B)(4.41B)(2.76B)
Debt Repayment(2.8B)(1.23B)(3.14B)(894M)2.07B
Common Stock Issued186M188M195M187M199.76M
Common Stock Repurchased(382M)(497M)(593M)(302M)(5.68B)
Dividends Paid(4.01B)(4.17B)(4.45B)(4.7B)(5.39B)
Other Financing Activities(48M)(111M)(63M)(50M)(472.87M)
Financing Cash Flow(7.06B)(5.82B)(8.05B)(5.76B)(9.26B)
Effect of Forex Changes15M8M(32M)(13M)862.16M
Net Change in Cash(3.82B)2.64B(4.03B)(1.27B)970.51M
Free Cash Flow8.48B8.42B7.35B5.89B10.14B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.